Table 1.
Patient Characteristics (N = 69)
| Characteristic | No. (%) |
|---|---|
| Age, y, median (IQR) | 61 (53–70) |
| Sex | |
| Male | 47 (68) |
| Female | 22 (32) |
| Country | |
| United States | 66 (96) |
| Southeast | 26 (38) |
| Midwest | 21 (30) |
| Southwest | 14 (20) |
| West | 4 (4) |
| Northeast | 1 (1) |
| International | 3 (4) |
| Immunocompromising condition | |
| None | 36 (52) |
| Solid organ transplant | 15 (22) |
| Malignancy on chemotherapy | 8 (12) |
| Other chronic immunosuppression | 7 (10) |
| HIV | 5 (7) |
| Other | 2 (3) |
| Comorbidity | |
| Diabetes | 28 (41) |
| Any chronic immunosuppressant | 27 (39) |
| Multiple agents | 16 (23) |
| Glucocorticoids | 17 (25) |
| Calcineurin inhibitors | 13 (19) |
| Antimetabolite | 11 (16) |
| T-cell co-stimulation blocker | 2 (3) |
| Alkylating agent | 2 (3) |
| Tyrosine kinase inhibitor | 2 (3) |
| Anti-CD20 | 1 (1) |
| mTOR inhibitor | 1 (1) |
| Year of COVID-19 diagnosis | |
| 2020 | 15 (22) |
| 2021 | 40 (58) |
| 2022 | 8 (12) |
| Unknown | 5 (7) |
| COVID-19 treatment | |
| Hospitalization for COVID-19 | 56 (81) |
| Supportive care only | 13 (19) |
| Any immunosuppressant | 51 (74) |
| Glucocorticosteroids | 50 (72) |
| IL-6 inhibitor | 7 (10) |
| JAK inhibitor | 5 (7) |
| Antiviral | 39 (57) |
| Remdesivir | 38 (55) |
| Paxlovid | 1 (1) |
| Antibody | 15 (22) |
| Convalescent plasma | 9 (13) |
| Monoclonal antibodies | 6 (9) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: COVID-19, coronavirus disease 2019; HIV, human immunodeficiency virus; IL-6, interleukin 6; IQR, interquartile range; JAK, Janus kinase; mTOR, mammalian target of rapamycin.